rna-binding

PTBP1-RNA-binding inhibitor P6 TFA (PTBP1 α3-helix derived peptide P6 TFA) is a specific stapled peptide inhibitor of the splicing factor PTBP1, which is used to inhibit RNA alternative splicing events regulated by PTBP1. PTBP1-RNA-binding inhibitor P6 TFA exerts its effects by binding to the RNA recognition motif of PTBP1.

UNC4976 TFA, a positive allosteric modulator (PAM) peptidomimetic of the CBX7 chromodomain, promotes binding to nucleic acids. It concurrently inhibits the H3K27me3-specific recruitment of CBX7 to target genes and enhances non-specific interaction with DNA and RNA [1].

TAT-CIRP, a trans-activating (Tat) cold-inducible RNA-binding protein-derived peptide, functions as an inhibitor of myeloid differentiation protein 2 (MD2). It has demonstrated significant neuroprotective effects against ischemic and hemorrhagic stroke in mouse models [1].

PTBP1α3-helix derived peptide P1 is a polypeptide that inhibits RNA binding [1].

Tat-CIRP, a peptide inhibitor, impedes the protein-protein interaction between myeloid differentiation 2 (MD-2), also known as lymphocyte antigen 96 (LY96), and cold-inducible RNA binding protein (CIRP) by binding to MD-2. This disrupts the MD-2 and CIRP interaction as confirmed in co-immunoprecipitation assays. Notably, in vivo studies reveal that Tat-CIRP, at dosages of 10 and 20 mg/kg, significantly reduces infarct volume in both a mouse model of middle cerebral artery occlusion (MCAO) and a rhesus monkey model of thrombosis-induced stroke. Additionally, it improves motor function, evidenced by decreased time to manipulate and withdraw food with the affected arm in the primate model.